|Day Low/High||94.47 / 96.35|
|52 Wk Low/High||81.12 / 121.75|
Here are Thursday's top research calls, including downgrades for CVS, Edwards Lifesciences and Qorvo, and an upgrade for Tesoro.
However, more consolidation may be needed before the uptrend resumes.
The small business survey signals more building, more hiring, and more buying, Jim Cramer says.
Still, volume and positive money flow will need to improve to sustain a breakout move in the name.
The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.
As the dominant player in the transcatheter aortic valve replacement market, Edwards doesn't 'need' large deals.
Insiders at these companies have been scooping up shares of their own stock lately.
Cramer says he likes Twilio for the long term and is taking Nvidia over Himax.
When it comes to growth, what's good for the American people may also now be good for stocks, Cramer says.
Additionally, Edwards Board Approves New $1 Billion Share Repurchase Program
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Jim Cramer says UVE is not bad, and he likes AIG and ALL as well.
Jim Cramer names companies with credibility, like NXPI and AAPL, and those that don't have it, including FIT.
Here's a window into what institutional investors may be doing and how to profit from that.
Cramer shares his views on takeover talks. NXP Semiconductor, Apple and Citigroup are among the stocks discussed.
Strong demand drives results and gains for Boeing, Akamai and others.
But several airline and retail stocks are proving highly volatile.
Edwards Lifesciences' (EW) 2016 third quarter revenue fell short of analysts' estimates.
Edwards Lifesciences is plunging on its earnings results. Cramer says investors should buy it.
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.